Vancomycin Oral

DRUG4 trials

Sponsors

St. Luke's Hospital, Chesterfield, Missouri, University of Kansas Medical Center, Radboud University Medical Center, Leiden University Medical Center

Conditions

Clostridioides DifficileClostridium Difficile InfectionClostridium Difficile Infection RecurrenceClostridium InfectionsCoronary Artery DiseaseEnterocolitis, PseudomembranousExtracorporeal Circulation; ComplicationsPostoperative Shock

Phase 4

Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics

CompletedNCT02951702

St. Luke's Hospital, Chesterfield, MissouriClostridium Difficile Infection, Prophylaxis, Vancomycin

Start: 2016-11-30End: 2017-07-31Updated: 2017-12-27

Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection

CompletedNCT03880539

University of Kansas Medical CenterClostridium Difficile Infection Recurrence

Start: 2019-06-25End: 2021-11-18Updated: 2022-05-26

Bezlotoxumab Versus FMT for Multiple Recurrent CDI

WithdrawnNCT05077085

Leiden University Medical CenterClostridioides Difficile, Clostridium Infections, Enterocolitis, Pseudomembranous

Start: 2022-01-31End: 2024-12-31Updated: 2023-03-28

Unknown Phase

The Effects of Gut Micribiota Disruption on the Immune Response After Open Heart Surgery

Radboud University Medical CenterCoronary Artery Disease, Extracorporeal Circulation; Complications, Postoperative Shock +1

Start: 2022-03-31End: 2023-03-31Target: 80Updated: 2021-03-12